Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.

Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH.

Eur J Cancer. 2019 Mar;109:92-102. doi: 10.1016/j.ejca.2018.12.022. Epub 2019 Jan 29.

2.

NRAS mutations are rare in colorectal cancer.

Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S.

Diagn Mol Pathol. 2010 Sep;19(3):157-63. doi: 10.1097/PDM.0b013e3181c93fd1.

3.

DNA methylation in the rectal mucosa is associated with crypt proliferation and fecal short-chain fatty acids.

Worthley DL, Whitehall VL, Le Leu RK, Irahara N, Buttenshaw RL, Mallitt KA, Greco SA, Ramsnes I, Winter J, Hu Y, Ogino S, Young GP, Leggett BA.

Dig Dis Sci. 2011 Feb;56(2):387-96. doi: 10.1007/s10620-010-1312-4. Epub 2010 Jul 16.

PMID:
20635146
4.

HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.

Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S.

Am J Pathol. 2010 May;176(5):2292-301. doi: 10.2353/ajpath.2010.090972. Epub 2010 Apr 2.

5.

Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.

Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S.

J Mol Diagn. 2010 Mar;12(2):177-83. doi: 10.2353/jmoldx.2010.090106. Epub 2010 Jan 21.

6.

DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer.

Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt KA, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA.

Oncogene. 2010 Mar 18;29(11):1653-62. doi: 10.1038/onc.2009.449. Epub 2009 Dec 7.

PMID:
19966864
7.

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Goldberg RM, Bertagnolli MM, Fuchs CS; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Canadian Cancer Society Research Institute; Southwest Oncology Group.

Clin Cancer Res. 2009 Dec 1;15(23):7322-9. doi: 10.1158/1078-0432.CCR-09-1570. Epub 2009 Nov 24.

8.

Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS.

Clin Cancer Res. 2009 Oct 15;15(20):6412-20. doi: 10.1158/1078-0432.CCR-09-1438. Epub 2009 Oct 13.

9.

Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Am J Gastroenterol. 2010 Feb;105(2):420-33. doi: 10.1038/ajg.2009.578. Epub 2009 Oct 6.

10.

CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.

Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S.

Int J Cancer. 2010 Jun 15;126(12):2863-73. doi: 10.1002/ijc.24908.

11.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2765-72. doi: 10.1158/1055-9965.EPI-09-0490. Epub 2009 Sep 29.

12.

p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis.

Ogino S, Nosho K, Shima K, Baba Y, Irahara N, Kirkner GJ, Hazra A, De Vivo I, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2513-21. doi: 10.1158/1055-9965.EPI-09-0451. Epub 2009 Sep 1.

13.

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2009 Sep 20;27(27):4591-8. doi: 10.1200/JCO.2009.22.8858. Epub 2009 Aug 24.

14.

A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.

Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Gastroenterology. 2009 Nov;137(5):1609-20.e1-3. doi: 10.1053/j.gastro.2009.08.002. Epub 2009 Aug 14.

15.

A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer.

Worthley DL, Le Leu RK, Whitehall VL, Conlon M, Christophersen C, Belobrajdic D, Mallitt KA, Hu Y, Irahara N, Ogino S, Leggett BA, Young GP.

Am J Clin Nutr. 2009 Sep;90(3):578-86. doi: 10.3945/ajcn.2009.28106. Epub 2009 Jul 29.

PMID:
19640954
16.

Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.

Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S.

Clin Cancer Res. 2009 Jul 15;15(14):4665-73. doi: 10.1158/1078-0432.CCR-09-0401. Epub 2009 Jul 7.

17.

A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases.

Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Clin Cancer Res. 2009 Jul 1;15(13):4431-8. doi: 10.1158/1078-0432.CCR-08-3330. Epub 2009 Jun 23.

18.

A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis.

Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, Toyoda S, Chen L, Kirkner GJ, Wolpin BM, Chan AT, Giovannucci EL, Fuchs CS.

Am J Gastroenterol. 2009 Aug;104(8):2047-56. doi: 10.1038/ajg.2009.281. Epub 2009 Jun 9.

19.

A cohort study of p27 localization in colon cancer, body mass index, and patient survival.

Ogino S, Shima K, Nosho K, Irahara N, Baba Y, Wolpin BM, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1849-58. doi: 10.1158/1055-9965.EPI-09-0181.

20.

DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.

Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS, Ogino S.

Clin Cancer Res. 2009 Jun 1;15(11):3663-71. doi: 10.1158/1078-0432.CCR-08-2383. Epub 2009 May 26.

21.

SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S.

Mod Pathol. 2009 Jul;22(7):922-32. doi: 10.1038/modpathol.2009.49. Epub 2009 May 8.

22.

Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.

Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S.

Neoplasia. 2009 May;11(5):418-25.

23.

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS.

J Clin Oncol. 2009 Mar 20;27(9):1477-84. doi: 10.1200/JCO.2008.18.6544. Epub 2009 Feb 23.

24.

Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis.

Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS.

Gastroenterology. 2009 Apr;136(4):1242-50. doi: 10.1053/j.gastro.2008.12.048. Epub 2008 Dec 24.

25.

JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype.

Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS, Ogino S.

Neoplasia. 2009 Jan;11(1):87-95.

26.

Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.

Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL, Fuchs CS.

Clin Cancer Res. 2008 Dec 15;14(24):8221-7. doi: 10.1158/1078-0432.CCR-08-1841.

27.

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S.

PLoS One. 2008;3(11):e3698. doi: 10.1371/journal.pone.0003698. Epub 2008 Nov 12.

28.
29.

Demonstration of adiponectin receptors 1 and 2 mRNA expression in human breast cancer cells.

Takahata C, Miyoshi Y, Irahara N, Taguchi T, Tamaki Y, Noguchi S.

Cancer Lett. 2007 Jun 8;250(2):229-36. Epub 2006 Nov 22.

PMID:
17123704
30.

Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.

Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S.

Cancer Lett. 2006 Nov 8;243(1):23-31. Epub 2006 Mar 23.

PMID:
16556483
31.

Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastia.

Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S, Harada N.

Endocr Res. 2005;31(3):219-27.

PMID:
16392624
33.

Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2005 Feb 15;11(4):1380-5.

34.

Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.

Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura J, Irahara N, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.

Eur J Cancer. 2003 Nov;39(17):2531-7.

PMID:
14602139

Supplemental Content

Loading ...
Support Center